Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16715881 | 0.92 | MOGAT2 (1.00) | MOGAT2 | |
| SCHEMBL15435223 | 0.91 | MOGAT2 (0.85) | MOGAT2 | |
| SCHEMBL16715847 | 0.90 | MOGAT2 (1.00) | MOGAT2 | |
| SCHEMBL16715857 | 0.89 | MOGAT2 (1.00) | MOGAT2 | |
| SCHEMBL15435335 | 0.89 | MOGAT2 (1.00) | MOGAT2 | |
| SCHEMBL16715850 | 0.89 | MOGAT2 (1.00) | MOGAT2 | |
| SCHEMBL16715822 | 0.87 | MOGAT2 (0.85) | MOGAT2 | |
| SCHEMBL16715885 | 0.87 | MOGAT2 (0.89) | MOGAT2 | |
| SCHEMBL16715884 | 0.86 | MOGAT2 (1.00) | MOGAT2 | |
| SCHEMBL16715854 | 0.85 | MOGAT2 (0.85) | MOGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687507-B1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-03-09 | — | — | EP | disclosed |
| US-9035059-B2 | Nitrogen-containing condensed heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| US-9035059-B2 | Nitrogen-containing condensed heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| US-9035059-B2 | Nitrogen-containing condensed heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| EP-2687507-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140005382-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005382-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | LCAT, ACAT2, SOAT2 | MOGAT2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.